Clinical Trial for Evenamide in Japan Commences

Newron Pharmaceuticals S.p.A. announces that its partner, EA Pharma, a subsidiary of Eisai, has initiated a Phase III clinical trial for evenamide in Japan. This trial is set to assess the efficacy, safety, and tolerability of EA8001, a glutamate modulator used as an add-on therapy for patients with treatment-resistant schizophrenia.

The study is a multicenter, randomized, double-blind, placebo-controlled trial. It targets patients inadequately responding to at least two different antipsychotics. EA Pharma sees this as a crucial step towards addressing the needs of those with schizophrenia by providing a potential new treatment option.

Evenamide has shown promise in prior studies, meeting key endpoints such as the Positive and Negative Syndrome Scale, indicating its potential as a novel therapy. The alliance empowers EA Pharma to develop and commercialize evenamide in Japan and other Asian markets.